Further delaying your preventative cancer care may cause more harm than good. Expert from Rutgers Cancer Institute of New Jersey explains how most colorectal cancers can be prevented through regular screenings, and it is safe to get your screenings, even during these difficult times.
Stay-at-home orders during the COVID-19 pandemic has resulted in an increased need for blood and platelets. Rutgers Cancer Institute expert shares why right now is an important time to donate blood to ensure a sufficient blood supply for patients in need.
July is UV Safety Month, the perfect time to raise awareness about the risk of developing sun-related skin cancer. Rutgers Cancer Institute expert shares tips about how to reduce skin cancer risk during the summer months when UV rays are the strongest.
The American Cancer Society recently updated its nutrition and physical activity guidelines for cancer prevention. These updates focus on increasing physical activity and developing healthy eating patterns at every age, with an emphasis on maintaining a healthy body weight through all stages of life.
A new study led by Rutgers Cancer Institute of New Jersey and the Gift of Life Marrow Registry seeks to determine how different versions of immune-vital genes screened for transplant matching may shape who develops or resists COVID-19.
Many people are worried about things in their lives that have been put on hold. For some women, this includes an annual mammogram. Safeguards have been put in place at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health facilities so women can safely continue to get this potentially life-saving screening or any follow-up care that may be needed.
Cancer patients might still have heightened concerns over rescheduling a postponed surgery or scheduling a new surgery right now due to COVID-19. Rutgers Cancer Institute of New Jersey expert explains how surgical care precautions have been instituted to ensure the safety of patients and medical staff.
June is Men’s Health Month, a national recognition that raises awareness about health care for men. It is also the month during which we celebrate Father’s Day. In celebration of these observances, an expert from Rutgers Cancer Institute of New Jersey shares information on cancer screenings and other important tips to encourage dad to lead a healthy lifestyle all year round.
Minimizing your exposure to COVID-19 doesn’t require sacrificing cancer care or preventive services. Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are taking extra precautions to ensure that patients can continue to receive exceptional care close to home.
Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.
Bruce G. Haffty, MD, associate vice chancellor for cancer programs and chair, radiation oncology at Rutgers Cancer Institute of New Jersey has been selected as the 2020 Gold Medal Award winner by the American Society for Radiation Oncology (ASTRO), a prestigious national award recognizing individuals who have made outstanding lifetime contributions in the field of radiation oncology.
Researchers from Rutgers Cancer Institute of New Jersey along with collaborators from Princeton University identify a new drug that has therapeutic effect against the aggressive hematological disease T-cell acute lymphoblastic leukemia.
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
While most public, hospital and academic libraries are closed to visitors due to the COVID-19 pandemic, there is a wealth of information available online, especially for cancer patients seeking disease specific information. Rutgers Cancer Institute of New Jersey's medical librarian shares some tips.
Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.
Research from investigators at Rutgers Cancer Institute of New Jersey shows that a cellular process known as autophagy promotes survival in mouse models by suppressing oxidative stress and a tumor suppressor known as p53.
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).
Along with a healthy lifestyle, regular screening can help with the prevention of cancer. Rutgers Cancer Institute of New Jersey experts share additional information during this Cancer Prevention Month.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Rutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective.
Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations. These may help further guide treatment decision making for patients.
Investigators at Rutgers Cancer Institute of New Jersey conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates along with good-to-excellent patient-reported cosmetic outcomes.
A Rutgers Cancer Institute of New Jersey investigator and other collaborators examined prenatal screening practices for blood disorders between different types of care providers and found different variations in prenatal guidance.
Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.
In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute
investigators and other collaborators examined characteristics, treatment patterns and outcomes and determined accurate diagnosis of the disease requires ongoing analysis.
The GO2 Foundation for Lung Cancer has awarded $250,000 to investigators at Rutgers Cancer Institute of New Jersey and Princeton University toward the identification and development of novel strategies to address treatment resistance in non-small cell lung cancer.
Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.
A $150,000 pledge from the Om Foundation will aid investigators at Rutgers Cancer Institute of New Jersey in examining a certain type of medication that impacts gene activity in the treatment of a form of pediatric brain cancer.
More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.
Reaffirming its commitment to continued growth and excellence, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health welcome Carolyn Hayes, PhD, RN, NEA-BC, as the new Chief Nursing Officer, RWJBarnabas, Oncology Services and Rutgers Cancer Institute.
One of the hallmarks of a National Cancer Institute-designated Comprehensive Cancer Center is the unique oncology expertise exhibited by its clinical team, including board certified oncology pharmacists. A Rutgers Cancer Institute of New Jersey expert shares more on their role in patient care.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, clears up some misconceptions about breast cancer.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, shares expertise on breast cancer prevention and advances in breast cancer care.
Although cure rates for children with cancer are increasing, cancer treatments can cause permanent deterioration of brain functions leading to impairments in attention, concentration, memory and learning. With the aid of a $3.4 million NIH grant, a Rutgers Cancer Institute of New Jersey investigator and others are exploring an approach that would detect these changes among children with acute lymphoblastic leukemia early during treatment. The goal is to identify a subset of patients who would benefit from a behavioral intervention or treatment clinical trial.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, shares expertise on breast cancer risk factors and screening.
As more women live with breast cancer, minimization of significant deformity in the breast after breast preservation is increasingly gaining attention. A Rutgers Cancer Institute of New Jersey surgical oncologist shares some insight.
Ovarian Cancer is expected to impact 22,000 U.S. women this year. Rutgers Cancer Institute of New Jersey Gynecologic Oncologist Dr. Mihae Song shares some facts during this Ovarian Cancer Awareness Month.
September is Thyroid Cancer Awareness Month and Dr. Amanda Laird, Chief of Endocrine Surgery at Rutgers Cancer Institute of New Jersey shares information on types of thyroid cancer, how it is diagnosed and treatment options.
In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.
From maintaining regular check-ups and keeping up to date with recommended vaccinations to a good diet and exercise, some simple tips can help keep youngsters healthy as they head back to class - and are cancer preventive too.
An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year. Although leukemias are thought to occur in childhood, they can actually present at any age in both children and adults.